Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
CONCLUSION: The probability of nodal positivity after neoadjuvant chemotherapy was less than 3 per cent in patients with TNBC or HER2-positive disease who achieved a breast rCR on MRI. These patients could be included in trials investigating the omission of sentinel node biopsy after neoadjuvant chemotherapy.
PMID: 33031572 [PubMed - as supplied by publisher]
Source: The British Journal of Surgery - Category: Surgery Authors: van der Noordaa MEM, van Duijnhoven FH, Cuijpers FNE, van Werkhoven E, Wiersma TG, Elkhuizen PHM, Winter-Warnars G, Dezentje V, Sonke GS, Groen EJ, Stokkel M, Vrancken Peeters MTFD Tags: Br J Surg Source Type: research
More News: Breast Cancer | Breast Needle Aspiration | Breast Surgery | Cancer | Cancer & Oncology | Chemotherapy | Fine Needle Aspiration | HER2 | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Surgery | UK Health | Ultrasound